时间： 2025 年 12 月 18 日（星期四）14:30–16:00 地点： 上海交通大学医学院 规模： 15-25 人 面向对象： 医疗器械创业公司 CEO、市场 / 品牌负责人 主分享嘉宾： 思宇MedTech医疗科技媒体矩阵创始人兼主编 赵清 本次活动 围 绕 传播在企业发展中的真实作用、趋势、方法讨论 展开， 主要是帮助业内同行认识和交流。 内容包括但不限于： 创业型公司 成长期、临床驱动型公司 上市公司 / 准上市公司 不同类型企业，传播重点如何取舍？ PR 是否仍被简单理解为"发稿与曝光"？ 当预算受限时，PR 应该 做减法，还是换打法 ？ 企业传播如何从"零散内容输出"，走向 可被反复使用的认知资产 ？ 哪些内容，真正能在融资、市场推广、医院沟通等关键场景中持续发挥作用？ 何时启动宣传工作？ 对谁说、说什么、不说什么？ 传播如何真正服务于医生决策，而不仅仅是产品信息呈现？ 临床内容如何从"专业正确"走向"对决策有用"？ 延展探讨｜出海公司（讨论） 如果还有其他想讨论的内容，请在报名填表时备注。 活动形式 12月底和1月份，还将在北京、深圳召开同主题活动，欢迎关注。 报名方法： 复制如下链接到 ...

文章来源： 八大处整形概念验证中心 转载要求：可以直接转载，请在文首注明来源 过去十年，整形外科与再生医学领域的技术创新并不缺少想法，更不缺论文、专利和早 期成果。真正的难点在于：如何让这些成果跨越 " 死亡之谷 " ， 从实验室原理走向可 验证的原型，再进入量产体系，最终成为真正被临床采用、被市场认可的产品。 在这一背景下，北京八大处整形科技发展有限公司牵头建设的 八大处整形医学概念验 证中心 ，成为国内首个专注整形外科科技成果转化的专业平台。 2025 年 10 月31 日 ，在 第三届八大处整形美容产业论坛 · 主论坛中， 北京八大处整形科技发展有限公司 姚贵金总经理 系统介绍了 平台建设思路、组织架构与实践探索 ，为整形与医美行业提 供了一个可参考的 " 创新到产业化 " 路径 。 活动回顾： 科技引领整形，创新驱动未来：第三届八大处整形美容产业论坛圆满召开 圆满落幕！第三届整形外科创新转化大赛决赛 一、概念验证：创新转化的核心环节 1. 概念验证是什么？ 概念验证（Proof of Concept, PoC）是创新走向产业化的关键节点，强调以最小成本、最快速度验证技术的 科学性、可量产性与商业价值。 ...

Investment Rating - Industry investment rating is "Outperform" compared to the market, expecting the industry index to perform better than the CSI 300 index by more than 5% in the next six months [22]. Core Insights - The medical device bidding environment remains robust, with a significant trend towards high-end products. Since 2025, the release of equipment update policy dividends has led to sustained market demand growth, keeping bidding activities at a high level. Monthly procurement scales from July to November 2025 were 13.4 billion, 14.6 billion, 16.4 billion, 16.4 billion, and 20.9 billion respectively, with year-on-year growth rates of +24%, +31%, +2%, +14%, and +0% [3][11]. - The bidding environment is benefiting leading companies in the industry, with procurement scales for ultrasound, CT, MRI, DR, DSA, and gastrointestinal endoscopes showing significant year-on-year growth in November 2025 [4][12][14]. - The report emphasizes the importance of high-end and intelligent medical devices, suggesting that leading domestic companies like Mindray, United Imaging, Kaili Medical, and Aohua Endoscopy should be closely monitored for their strategic positioning in the market [5][20]. Summary by Sections Market Trends - The medical device market is experiencing a strong revival, with a notable focus on high-end imaging equipment such as CT, MRI, and ultrasound, which together account for nearly 62% of the total bidding amount [3][11]. - In November 2025, the procurement scale for ultrasound was 2.301 billion (yoy +17%), CT was 2.605 billion (yoy +26%), MRI was 2.394 billion (yoy +6%), DR was 460 million (yoy +50%), and DSA was 1.016 billion (yoy +4%) [12][14]. Company Performance - Domestic companies are aligning with industry trends, with Mindray achieving 1.318 billion (yoy +12%), United Imaging at 1.433 billion (yoy +30%), Kaili Medical at 247 million (yoy +62%), and Aohua at 109 million (yoy +60%) in November 2025 [17]. Investment Recommendations - The report recommends focusing on domestic leading enterprises that are enhancing their high-end and intelligent product offerings, as the bidding environment is expected to remain favorable due to ongoing policy support for equipment updates [5][20].

证券日报网讯 12月11日晚间，开立医疗发布公告称，公司决定将向特定对象发行股份的募投项目"松山 湖开立医疗器械产研项目"达到预定可使用状态日期由2025年12月31日调整至2026年12月31日，"总部基 地建设项目"调整至2027年12月31日，项目实施主体、募集资金投资用途及投资规模均不变。 （文章来源：证券日报） ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][9] Core Insights - The company is a pioneer in the ultrasound field, focusing on portable and intelligent solutions, with a strong outlook for external collaborations [2][8] - The company has a comprehensive product lineup that includes high-end ultrasound machines and portable devices, which are competitive in both domestic and international markets [8][60] - The financial projections indicate steady revenue growth, with expected revenues of 5.17 billion, 6.21 billion, and 7.45 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 1.46 billion, 1.82 billion, and 2.29 billion yuan [7][9] Summary by Sections 1. Company Overview - Founded in 1996, the company has focused on ultrasound technology, holding over 400 intellectual property rights and exporting products to more than 100 countries [18][21] - The company has established R&D centers in both China and the US, and has been involved in significant national research projects [18] 2. Market Potential - The global ultrasound market is projected to grow, with a compound annual growth rate (CAGR) of 9% expected from 2020 to 2024 [43] - The domestic ultrasound market is also expanding, with significant breakthroughs from local companies [47] 3. Product Development - The company has developed a complete range of ultrasound products, including high-end and portable devices, which are recognized for their performance and innovation [60][67] - The SonoFamily series includes advanced products like XBit90, SonoMax, SonoAir, and SonoEye, which leverage AI technology for enhanced diagnostic capabilities [60][66] 4. Financial Performance - The company has shown stable financial performance, with a projected revenue of 4.69 billion yuan in 2024, despite a slight decline due to external factors [27][32] - The gross margin remains stable at around 59%, with a low debt ratio of 11% as of Q3 2025 [34][38] 5. Strategic Collaborations - The company is actively pursuing external collaborations, including ODM partnerships with major global firms like Philips and the Gates Foundation, which are expected to enhance growth prospects [79][81]

Core Viewpoint - The article maintains an "overweight" rating, recommending medical device companies that are expected to benefit from the implementation of equipment upgrade policies leading to performance recovery [1] Group 1: Market Growth and Equipment Procurement - The scale of medical device bidding continues to grow, with significant increases in November 2025: MR up 11.1%, CT up 26.4%, DR up 47.2%, ultrasound up 17.0%, endoscopes down 4.9%, and surgical robots up 8.6% [2] - Cumulatively, by November 2025, the bidding scale for new equipment shows substantial growth: MR up 50.4%, CT up 72.7%, DR up 74.0%, ultrasound up 56.1%, endoscopes up 19.7%, and surgical robots up 32.8% [2] - Specific company performance in November 2025 includes: United Imaging MR up 3.0%, United Imaging CT up 41.9%, Mindray ultrasound up 24.5%, KAILI ultrasound up 70.2%, KAILI endoscope up 47.4%, and Aohua endoscope up 60.3% [2] - Year-to-date performance by November 2025 shows: United Imaging MR up 39.7%, United Imaging CT up 56.4%, Mindray ultrasound up 68.4%, KAILI ultrasound up 92.6%, KAILI endoscope up 87.8%, and Aohua endoscope up 26.1% [2] Group 2: Policy Impact and Market Recovery - The implementation of equipment upgrade policies is expected to drive long-term procurement levels in the medical device sector, with a target of over 25% growth in equipment investment by 2027 compared to 2023 [3] - In 2024, significant procurement plans for medical equipment are expected to be announced across various provinces, indicating a robust demand for innovative diagnostic and treatment equipment [3] - The domestic market is showing signs of recovery, with a reported revenue of 6.866 billion yuan for United Imaging in the first three quarters of 2025, reflecting a year-on-year growth of 23.70% [3]

证券日报网讯 12月11日晚间，开立医疗发布公告称，2025 年 12 月 10 日，公司第四届董事会第十三次 会议和第四届监事会第十二次会议，分别审议通过了《关于取消监事会、修订并办理工商变更登记的议 案》。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Kaili Medical (300633) as of December 11, 2025, with a closing price of 26.23 yuan, reflecting a decline of 2.16% [1] - The company reported a main revenue of 1.459 billion yuan for the first three quarters of 2025, an increase of 4.37% year-on-year, while the net profit attributable to shareholders decreased by 69.25% to 33.51 million yuan [2] - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year, but reported a net loss of 13.52 million yuan, which is an increase of 78.05% in losses compared to the previous year [2] Group 2 - The company has a debt ratio of 24.22% and reported investment income of 2.08 million yuan, with financial expenses amounting to -38.30 million yuan, and a gross profit margin of 60.36% [2] - Over the past 90 days, 15 institutions have provided ratings for the stock, with 10 buy ratings and 5 hold ratings, and the average target price set by institutions is 4.128 billion yuan [2] - On December 11, 2025, the net inflow of main funds was 1.12 million yuan, accounting for 1.48% of the total transaction amount, while retail investors saw a net inflow of 1.57 million yuan, representing 2.06% of the total transaction amount [1]

深圳开立生物医疗科技股份有限公司 年报信息披露重大差错责任追究制度 深圳开立生物医疗科技股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为进一步提高深圳开立生物医疗科技股份有限公司（以下简称"公 司"）的规范运作水平，加大对年报信息披露责任人的问责力度，提高年报信息 披露的质量和透明度，增强年报信息披露的真实性、准确性、完整性和及时性， 根据《中华人民共和国证券法》、《中华人民共和国会计法》、《上市公司信息披露 管理办法》、《上市公司治理准则》、《深圳证券交易所创业板股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《关 于要求制定上市公司年报信息披露重大差错责任追究制度的通知》等法律、法规、 规范性文件及《深圳开立生物医疗科技股份有限公司章程》（以下简称"《公司 章程》"）、《深圳开立生物医疗科技股份有限公司信息披露制度》（以下简称"《信 息披露管理制度"》）的有关规定，结合公司的实际情况，特制定本制度。 第二条 公司财务总监、财务会计人员、各部门负责人及其他相关人员应当 严格执行《企业会计准则》及相关规定，严格遵守公司与财务报告相关的内部控 ...

深圳开立生物医疗科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第一条 为规范公司董事及高级管理人员的选聘，优化董事会组成，进一步建 立健全深圳开立生物医疗科技股份有限公司（以下简称"公司"）董事及其他高 级管理人员的考核和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公 司法》（以下简称"公司法"）、《上市公司治理准则》（以下简称"治理准 则"）、《深圳证券交易所创业板股票上市规则》（以下简称"创业板上市规 则"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》（以下简称"规范运作"）、《上市公司独立董事管理办法》（以下简 称"独立董事管理办法"）和《深圳开立生物医疗科技股份有限公司章程》（以 下简称"公司章程"）及其他有关规定，公司特设董事会提名委员会，并制订本 工作细则。 第二条 提名委员会是董事会设立的专门工作机构，主要负责对公司董事和 高级管理人员的人选、选择标准和程序提出建议。 第三条 本细则所称董事是指在公司领取薪酬的董事，其他高级管理人员是指 董事会聘任的总经理、副总经理、董事会秘书和财务负责人。 第二章 人员组成 深圳开立生物医疗科技股份有限公司 ...